Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?

AbbVie is set to report Q2 2025 earnings on July 31, with consensus estimates at $15.07 billion in revenue and $2.89 EPS, though 2025 EPS estimates have recently declined. The company's top-line growth is expected to be primarily driven by strong sales of immunology drugs Skyrizi and Rinvoq, effectively mitigating the ongoing impact of Humira biosimilar erosion and competitive pressures on Imbruvica. While neuroscience sales show strength, the aesthetics segment faces headwinds; however, AbbVie projects robust high single-digit revenue CAGR through 2029, underscoring a successful transition post-Humira and diversified pipeline growth.

Analysis

AbbVie's upcoming Q2 2025 earnings report is pivotal for validating its post-Humira growth narrative. Consensus estimates project revenues of $15.07 billion and an EPS of $2.89, closely aligning with the company's guidance. The central dynamic is the continued sales ramp-up of immunology drugs Skyrizi and Rinvoq, with combined consensus estimates of $6.1 billion, which are expected to successfully offset the ongoing erosion of Humira sales (estimated at $1.41 billion) following its loss of exclusivity. While the core immunology franchise transition appears on track, the portfolio exhibits mixed performance. The neuroscience division remains a source of strength, with expected sales of $2.47 billion, but this is contrasted by headwinds from competition impacting the oncology drug Imbruvica and notable softness in the aesthetics franchise in the U.S. and China. Despite a positive long-term outlook, including a projected high single-digit revenue CAGR through 2029, near-term indicators warrant attention: full-year 2025 EPS estimates have been revised downward in the past 30 days, and the Zacks model indicates a neutral probability of an earnings beat. Valuation is also a key consideration, with the stock trading at 14.44x forward earnings, above its five-year average of 12.59x, reflecting the market's pricing-in of future growth.

Key Decisions for Investors

• Investors should closely monitor the Q2 sales figures for Skyrizi and Rinvoq to confirm they are meeting or exceeding expectations, as this is fundamental to AbbVie's long-term growth thesis.
• Attention should be paid to management's guidance on the aesthetics franchise and the competitive landscape for Imbruvica, as persistent weakness in these areas could offset gains elsewhere in the portfolio.
• Given the stock's valuation is above its historical average, long-term investors may consider any post-earnings price weakness as a potential buying opportunity, provided the core growth drivers remain intact.
• The recent downward revision of full-year EPS estimates suggests exercising caution around the near-term earnings catalyst, as a significant positive surprise may be unlikely.